PROMETIC GETS AUTHORIZATION FROM HEALTH CANADA TO BEGIN TRIAL FOR ANEMIA DRUG

ProMetic BioSciences has announced that it has received authorization from the Therapeutic Products Directorate of Health Canada to begin a Phase Ib/II clinical trial of PBI-1402, its novel therapeutic compound in development to treat patients with anemia.

The company plans to study the safety and efficacy of PBI-1402 in up to 30 cancer patients undergoing chemotherapy and suffering from anemia. This trial follows a prior Phase I trial, which displayed an excellent safety profile and an increase of reticulocyte numbers in the study subjects.